{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:56:04Z","timestamp":1790661364592,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Atopic dermatitis (AD) is a highly heterogeneous disease clinically and biologically. Serum biomarkers have been utilized for endotype identification and have the potential to be predictors for treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore the serum biomarker-based endotypes of Chinese patients with AD and to identify biomarkers for prediction of the efficacy of dupilumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sera from 125 patients with moderate-to-severe AD and 60 normal controls (NC) were analysed for 24 cytokines\/chemokines using the magnetic Luminex assay. After the patients received 16 weeks of dupilumab treatment, the efficacy was evaluated, and blood eosinophils, serum immunoglobulin (Ig) E and biomarkers were measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Chinese patients with moderate-to-severe AD were characterized by T-helper (Th)2-dominant serum biomarkers that were mixed with differentially increased Th1-, Th17- and Th22-type cytokines\/chemokines, and it was mainly Th2-type serum biomarkers that were positively correlated with disease severity and eosinophil counts. Adult (but not adolescent or elderly) patients with AD showed a consistent and more significant increase of biomarkers across different types of inflammation. The patients were grouped into two clusters by unsupervised k-means analysis, which were differentially associated with inflammation. Treatment with dupilumab decreased the levels of most cytokines\/chemokines analysed. While there was no difference between the two clusters in the efficacy of dupilumab, baseline levels of CD25\/soluble interleukin (sIL)-2R\u03b1, IL-31 and IL-36\u03b2 were identified as predictive factors associated with the efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study revealed two inflammation-related endotypes of Chinese patients with AD based on serum biomarkers. High levels of CD25\/sIL-2R\u03b1, IL-31 and IL-36\u03b2 might predict good efficacy of dupilumab treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad032","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:23:31Z","timestamp":1675952611000},"page":"649-660","source":"Crossref","is-referenced-by-count":52,"title":["Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab"],"prefix":"10.1093","volume":"188","author":[{"given":"Yuemeng","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai, 200040 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai, 200040 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangshang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai, 200040 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai, 200040 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoqiong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai, 200040 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College , Nanjing 210042 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai, 200040 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, and The Key Laboratory of Public Health Safety of Ministry of Education, Fudan University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College , Nanjing 210042 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology , Shanghai, 200040 , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"2023100619302505900_ljad032-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"2023100619302505900_ljad032-B2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023100619302505900_ljad032-B3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023100619302505900_ljad032-B4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/all.12184","article-title":"Immunology of atopic eczema: overcoming the Th1\/Th2 paradigm","volume":"68","author":"Eyerich","year":"2013","journal-title":"Allergy"},{"key":"2023100619302505900_ljad032-B6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jaci.2020.08.041","article-title":"Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities","volume":"147","author":"He","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B7","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2018.02.047","article-title":"Serum from Asian patients with atopic dermatitis is characterized by T(H)2\/T(H)22 activation, which is highly correlated with nonlesional skin measures","volume":"142","author":"Wen","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B9","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1111\/jdv.16346","article-title":"Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China","volume":"34","author":"Wang","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100619302505900_ljad032-B10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jaci.2017.12.991","article-title":"Serum biomarker profiles suggest that atopic dermatitis is a systemic disease","volume":"141","author":"Thijs","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","article-title":"The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults","volume":"148","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2019.10.039","article-title":"The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature","volume":"82","author":"Pavel","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023100619302505900_ljad032-B13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","article-title":"Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis","volume":"140","author":"Thijs","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2020.04.062","article-title":"Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers","volume":"147","author":"Bakker","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaci.2021.06.029","article-title":"Unraveling heterogeneity in pediatric atopic dermatitis: identification of serum biomarker based patient clusters","volume":"149","author":"Bakker","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B16","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/exd.14389","article-title":"Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease","volume":"30","author":"Sims","year":"2021","journal-title":"Exp Dermatol"},{"key":"2023100619302505900_ljad032-B17","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jdv.18109","article-title":"Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study","volume":"36","author":"Gu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100619302505900_ljad032-B18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100619302505900_ljad032-B19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","article-title":"Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"90","author":"Wang","year":"2018","journal-title":"J Dermatol Sci"},{"key":"2023100619302505900_ljad032-B20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"2023100619302505900_ljad032-B22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl.","key":"2023100619302505900_ljad032-B23","first-page":"44","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin","year":"1980","journal-title":"Acta Dermato (Stockholm)"},{"key":"2023100619302505900_ljad032-B24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ebiom.2018.12.054","article-title":"Development and validation of an immune gene-set based prognostic signature in ovarian cancer","volume":"40","author":"Shen","year":"2019","journal-title":"EBioMedicine"},{"key":"2023100619302505900_ljad032-B25","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis \u2013 a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunology"},{"key":"2023100619302505900_ljad032-B26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1398-9995.2005.00774.x","article-title":"Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis","volume":"60","author":"Jahnz-Rozyk","year":"2005","journal-title":"Allergy"},{"key":"2023100619302505900_ljad032-B27","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2014.07.031","article-title":"Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity","volume":"71","author":"Landheer","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023100619302505900_ljad032-B28","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","article-title":"Atopic dermatitis displays stable and dynamic skin transcriptome signatures","volume":"147","author":"M\u00f6bus","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2222.1993.tb00310.x","article-title":"Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity","volume":"23","author":"Walker","year":"1993","journal-title":"Clin Exp Allergy"},{"key":"2023100619302505900_ljad032-B31","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1111\/all.14492","article-title":"EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers","volume":"75","author":"Bakker","year":"2020","journal-title":"Allergy"},{"key":"2023100619302505900_ljad032-B32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B33","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"2023100619302505900_ljad032-B34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B35","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jaci.2013.03.050","article-title":"Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation","volume":"132","author":"Stott","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2023100619302505900_ljad032-B36","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"727956","key":"2023100619302505900_ljad032-B37","article-title":"The role of IL-36 in the pathophysiological processes of autoimmune diseases","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad032\/49446770\/ljad032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/5\/649\/51917993\/ljad032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/5\/649\/51917993\/ljad032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T19:33:34Z","timestamp":1696620814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/5\/649\/7032168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,2,9]]},"published-print":{"date-parts":[[2023,4,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad032","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,2,9]]}}}